active
ACTIVE SINCE: 2013

Global Health Innovative Technology (GHIT) Fund

Japanese-led initiative aiming to discover and advance the development of new health technologies such as drugs, vaccines and diagnostic for low-and middle-income countries.
SGDS CONTRIBUTING TO:
MEMBER COMPANIES:
Academia or research institute 102
Private Foundation or Development Organization 3
Other Business Sector 3
Global NGOs 7
Other Business 5
Government 2
Life Sciences 9
Professional Services 1
Intergovernmental Organizations and Multilaterals 3
Local NGOs 5
Bilateral development organizations 1
Product Development Partnerships 1
Pharma (non-IFPMA member) 3
Technology 1
Objectives

Established in 2013, Global Health Innovative Technology (GHIT) is a Japanese-led initiative aiming to discover and advance the development of new health technologies such as drugs, vaccines and diagnostic for low-and middle-income countries.

Globalization and the unprecedented speed of cross-border infection in the 21st century has created the need for a global health strategy. Awareness of common global threats to the health of citizens has increased, and governments understand the need to work together to counteract these threats. Since 2000, the global community has focused on three of the biggest threats to human health – HIV, tuberculosis and malaria. In particular, the eradication of malaria and NTDs is listed as one of the 169 targets linked to the 17 United Nations’ Sustainable Development Goals (SDGs).

The Global Health Innovative Technology Fund (GHIT Fund), is Japan’s first public-private partnership to promote the creation of innovative treatment agents for infectious diseases that affect people in developing countries, such as malaria, tuberculosis, and neglected tropical diseases (NTDs).

The GHIT Fund was established by three key partners: the Government of Japan, the Bill & Melinda Gates Foundation and five Japanese leading pharmaceutical companies: Astellas Pharma, Daiichi Sankyo, Eisai, Shionogi, and Takeda Pharmaceutical. In 2018, there are now 11 full partners.

As the world’s first public-private partnership, GHIT Fund has facilitated research and development for neglected diseases, such as malaria, tuberculosis and NTDs. As antimicrobial resistance is also now a serious global health threat, GHIT supports AMR related projects. The combination of Japan’s government and its drug industry—the third largest in the world—brings Japan’s technology, innovation and insights to the development of drugs, vaccines and diagnostics for the developing world.

 

Company updates

Mitsubishi

  • Joint research with Medicines for Malaria Venture (MMV): The Company provided its pharmaceutical compound library (50,000 compounds) to Medicines for Malaria Venture (MMV), a research institution that focuses on the discovery of new anti-malaria drugs. Three types of promising hit compounds that have the potential to become pharmaceutical products have been identified. In addition, we promoted joint research and from one of these compounds, we acquired two lead compounds as new anti-malaria drug candidates. In April 2019, we will move to the next phase and continue conducting research in collaboration with MMV to create candidate compounds.
  • Joint research with Drugs for Neglected Diseases initiative (DNDi): Together with the Drugs for Neglected Diseases initiative (“DNDi”), an international organization involved in non-profit drug development, we began drug discovery research for lead compounds targeting Chagas disease and leishmaniasis in April 2021. MTPC and DNDi have been conducting compound discovery screening for these diseases since September 2019 and succeeded in acquiring nine types of hit compounds. Since the acquired hit compounds fulfilled the criteria for advancing to the lead compound search, the next step in drug discovery, we have set the acquisition of compounds that meet the lead stage criteria as the final goal of the two-year project.
Results and milestones

In 2016, GHIT Fund announced it was investing in a vaccine that could block the transmission of two species of malaria and a rapid fire test that can reveal a malaria infection in a matter of minutes.  It is also investing in the development of a new diagnostic test for tuberculosis (TB) by Fujifilm Corporation and Foundation for Innovative New Diagnostics, which can diagnose TB in HIV-positive patients.

In 2015 the GHIT Fund, its members Eisai, Shionogi and Takeda Pharmaceutical, along with partners the Drugs for Neglected Diseases initiative (DNDi) and AstraZeneca began a ground-breaking initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.

In 2013 Astellas received a $1.86 million grant to develop and register a new pediatric formulation of the gold standard treatment drug praziquantel to combat schistosomiasis.

In June 2013, with support from the GHIT Fund, Takeda began to work with Product Development Partners (PDPs), including MMV, TB Alliance and DNDi, in a program to screen Takeda’s drug compound library for new candidate compounds that might have the potential to be developed into new drugs for the treatment of infections particularly prevalent in developing countries, such as HIV, tuberculosis, malaria and neglected tropical diseases.

GHIT has provided grants of $5.7 million to six global partnerships developing innovative drugs and vaccines against malaria, tuberculosis and Chagas disease in the first round of request for proposal (RFP) in November, 2013.  Another $12 million grants for TB and NTDs were awarded to four innovative projects in the second round of RFP in March, 2014.

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Target Population
  • Children
  • Youth
  • Men
  • Women
  • People with low incomes
SGDs the partnership contributes to
SDG 3: Good Health and Wellbeing
  1. 3.2: Reduce Under-5 Mortality 
  2. 3.3: Communicable Diseases & NTDs
  3. 3.8: Achieve universal health coverage
SDG 5: Gender Equality
SDG 10: Reduced Inequalities
SDG 17: Partnerships for the Goals 
Partner organizations
Academia or research institute

McGill University

University of Massachusetts

Collective of Applied Studies and Social Development

Instituto Leonidas & Maria Deane

Penn State Hershey Medical Center

University of Copenhagen (UCPH)

Baylor College of Medicine

Muhimbili University of Health and Allied Sciences in Tanzania

University of Melbourne

Ehime University

Jichi Medical University

Research Institute of Tuberculosis

University of Kentucky

Bio21 Molecular Science and Biotechnology Institute

Nagasaki University

University of Minnesota

Fujita Health University

Juntendo University

Teikyo University

University of the Philippines- Manila, Philippines

Biomedical Primate Research Centre

National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand

University of Pennsylvania

Groupe de Recherche Action en Santé (GRAS)

Kanazawa University

Chemo-Sero-Therapeutic Research Institute

University of Toyama

Broad Institute

Research Institute for Microbial Diseases, Osaka University

Walter and Eliza Hall Institute of Medical Research

Gulu University

Keio University School of Medicine

Kitazato Institute

University of Tübingen (UKT)

Erasmus University

Sabin Vaccine Institute

University of Bonn

Hokkaido University

Kumamoto National Institute of Technology, Kumamoto College

Scripps Research Institute

Farmanguinhos

Harvard University

St. Jude Childrens Research Hospital

Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso

Hospital General de Mexico

Kyoto University

Tokyo Medical and Dental University

International Centre for Genetic Engineering and Biotechnology

High Energy Accelerator Research Organization (KEK)

Structural Genomics Consortium / University of Oxford

Noguchi Memorial Institute for Medical Research

Swiss Tropical and Public Health Institute

Leiden University Medical Center

Toyama Prefectural University

Ifakara Health Institute

Tokyo University

Barcelona Institute for Global Health (ISGlobal)

The Ohio State University

Medical Center for Translational Research Osaka University Hospital

Trustees of Dartmouth College Geisel School of Medicine

Insititute of Tropical Medicine Antwerp

Université Félix Houphouët-Boigny (UFHB) in Ivory Coast

Centre Pasteur du Cameroon (CPC)

Ohio University

Mycetoma Research Center (MRC)

Universidad Autònoma Juan Misael Saracho

International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B)

University of Buea

Asociación Civil Selva Amazónica

Colorado State University

Nagoya University

Universidad de Concepción, Chile (UC)

Johns Hopkins University

University of California, San Diego (UCSD)

Center for Health Promotion and Research (CHPR)

Institut de recherche pour le développement

National Institute of Biomedical Innovation, Health and Nutrition

Universidad Mayor de San Simon

KEMRI-Wellcome Trust Research Program

University of Cambridge

Centre de Recherches Médicales de Lambaréné (CERMEL)

Institut national de la santé et de la recherche médicale (Inserm)

National Institute of Infectious Diseases

Universidad Nacional de La Plata (UNLP)

Liverpool School of Tropical Medicine

University of Dundee

Centre National de Recherche et de Formation sur le Paludisme (CNRFP)

Institute of Microbial Chemistry

National Research Center for Protozoan diseases, Obihiro University of Agriculture and Veterinary Medicine

Universiti Sains Malaysia

London School of Hygiene & Tropical Medicine (LSHTM)

University of Florida

Centro para el Desarrollo de Investigación Científica (CEDIC)

Institute of Physical and Chemical Research (RIKEN)

National Science and Technology Development Agency

University at Buffalo, The State University of New York

Mahidol University

University of Liverpool

Charité –Universitätsmedizin Berlin

Instituto de Nutrición “Salvador Zubirán” México (IN)

Pasteur Institute Côte d’Ivoire

University of Chicago

Private Foundation or Development Organization

Wellcome Trust

Bill and Melinda Gates Foundation

SCI Foundation (SCI)

Other Business Sector

Platform of Integral Care for Patients with Chagas Disease

Raoul Follereau Institute Côte d’Ivoire

Klinikum rechts der Isar der Technischen Universität München, Department of Neurology, (MRI)

Global NGOs

Drugs for Neglected Diseases initiative (DNDi)

Aeras Global TB Vaccine Foundation

FIND Diagnostics

Global Alliance for TB Drug Development (TB Alliance)

Malaria No More

Mundo Sano

PATH

Other Business

Life Sciences

Professional Services

Pharma (non-IFPMA member)

Technology

Other Business Sector

Government

National Institute of Advanced Industrial Science and Technology, Japan

Japan

Life Sciences

Antigen Discovery, Inc.

Biopromic AB

ERADA Technology Alliance Ltd.

AI Biosciences Inc.

Latham BioPharm Group (Latham)

Mologen

Oasis Diagnostics Corporation

Ology Bioservices Inc.

TCG Lifesciences Pvt. Limited

Professional Services

Lygature

Intergovernmental Organizations and Multilaterals

Unitaid

UNDP

Coalition for Epidemic Preparedness Innovations (CEPI)

Local NGOs

Singapore Immunology Network

Ciencia y Estudios Aplicados Para el Desarrollo en Salud y Medio Ambiente (CEADES)

Drugs and Diagnostics for Tropical Diseases

Hope Commission International

European Vaccine Initiative

Bilateral development organizations

US Food and Drug Administration (US FDA)

Product Development Partnerships

Medicines for Malaria Venture (MMV)

Pharma (non-IFPMA member)

Gennova Biopharmaceuticals

InBios International, Inc.

VLP Therapeutics

Technology

SimCyp

Additional information

EXTERNAL RESEARCH